Live Analyst Rating Changes 54325 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Glen Santangelo
BARC

Glen Santangelo

Barclays
Wall Street Analyst
★★★☆☆
#1449
on 13Foresight · ranked by our own returns
61%
Success Rate
+6.6%
Average Return
72 of 118 calls profitable · +3.2% vs benchmark
S&P 500 (SPY)
🔒 3-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 61% of Glen Santangelo's ratings turned a profit when each position was held for 1 year — averaging +6.6% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.
Glen's Stock Coverage 48 ratings · 2026-11-09
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
LGND
Ligand Pharma
 Oct 30, 2026 BUY Strong Buy
-11.1% avg upside
16 analysts
$345.00
6.82% Upside
 -5.1% ·
TSE:BHC
Bausch Health Companies
 Oct 29, 2026 HOLD Buy
+386.9% avg upside
30 analysts
$9.78
14.68% Downside
 -7.6% ·
HIMS
Hims & Hers Health
 Oct 29, 2026 BUY Buy
+3.1% avg upside
23 analysts
$35.00
26.46% Upside
 -12.4% ·
ALGN
Align Tech
 Oct 29, 2026 BUY Strong Buy
+89.9% avg upside
21 analysts
$200.00
33.44% Upside
 +8.0% ·
INDV
Indivior
 Oct 28, 2026 BUY Strong Buy
+1.0% avg upside
10 analysts
$45.00
27.21% Upside
 +4.3% ·
CAH
Cardinal Health
 Oct 27, 2026 BUY Strong Buy
-14.3% avg upside
30 analysts
$275.00
9.73% Upside
 +10.2% ·
IL:TEVA
Teva
 Oct 15, 2026 BUY Strong Buy
+18.2% avg upside
8 analysts
$14779.46
15.50% Upside
 +2.0% ·
VTRS
Viatris
 Oct 15, 2026 BUY Buy
+25.5% avg upside
22 analysts
$22.00
15.55% Upside
 +4.1% ·
CTEV
Claritev
 Oct 13, 2026 BUY Strong Buy
+48.9% avg upside
8 analysts
$40.00
66.58% Upside
 -4.3% ·
PHR
Phreesia
 Oct 09, 2026 HOLD Strong Buy
+36.7% avg upside
22 analysts
$11.00
11.65% Downside
 +16.7% ·
MDLN
Medline
 Oct 09, 2026 BUY Strong Buy
+43.4% avg upside
27 analysts
$43.00
33.86% Upside
 +9.3% ·
AMRX
Amneal Pharmaceuticals
 Sep 21, 2026 BUY Buy
-10.1% avg upside
19 analysts
$20.00
7.09% Downside
 -0.1% ·
ALVO
Alvotech
 Sep 16, 2026 BUY Strong Buy
+87.4% avg upside
7 analysts
$8.00
71.99% Upside
 -8.4% ·
WAY
Waystar Holding Corp.
 Sep 15, 2026 HOLD Strong Buy
+34.9% avg upside
30 analysts
$30.00
7.05% Upside
 +10.2% ·
ANIP
ANI Pharmaceuticals
 Aug 25, 2026 BUY Strong Buy
+40.0% avg upside
12 analysts
$100.00
38.86% Upside
 -8.8% ·
ELAN
Elanco Animal Health
 Aug 21, 2026 BUY Strong Buy
+35.1% avg upside
20 analysts
$30.00
30.07% Upside
 -1.2% ·
XRAY
DENTSPLY SIRONA
 Aug 21, 2026 SELL Buy
+182.4% avg upside
25 analysts
$11.00
15.45% Upside
 +7.6% ·
DH
Definitive Healthcare Corp
 Aug 21, 2026 SELL Hold
+372.5% avg upside
19 analysts
$1.00
10.78% Downside
 -72.3% ·
GDRX
GoodRx Holdings
 Aug 20, 2026 SELL Buy
+270.4% avg upside
28 analysts
$4.00
14.67% Upside
 +1.4% ·
DOCS
Doximity
 Aug 20, 2026 HOLD Buy
+11.3% avg upside
28 analysts
$27.00
17.52% Downside
 +25.3% ·
MCK
McKesson
 Aug 18, 2026 BUY Strong Buy
-20.4% avg upside
29 analysts
$1000.00
0.56% Upside
 +22.2% ·
AMPH
Amphastar Pharmaceuticals
 Aug 18, 2026 HOLD Hold
-3.5% avg upside
11 analysts
$23.00
17.01% Downside
 +33.5% ·
ZTS
Zoetis
 Aug 17, 2026 HOLD Buy
+43.7% avg upside
25 analysts
$85.00
6.64% Upside
 +9.6% ·
NVST
Envista Holdings
 Aug 17, 2026 BUY Buy
+27.4% avg upside
19 analysts
$32.00
36.14% Upside
 -8.9% ·
COR
Cencora
 Aug 13, 2026 BUY Buy
-2.6% avg upside
45 analysts
$350.00
5.79% Upside
 +13.5% ·
IDXX
Idexx Laboratories
 Aug 11, 2026 BUY Buy
+30.3% avg upside
19 analysts
$710.00
28.75% Upside
 +15.2% ·
HSIC
Henry Schein
 Aug 05, 2026 BUY Buy
+9.6% avg upside
25 analysts
$100.00
17.79% Upside
 -4.8% ·
OGN
Organon
 Feb 24, 2026 SELL Sell
+7.4% avg upside
9 analysts
$8.00
42.23% Downside
 -70.3% ·
PGNY
Progyny
 Jul 21, 2025 BUY Strong Buy
+14.1% avg upside
15 analysts
$29.00
0.55% Downside
 +40.5% ·
HQY
Healthequity
 Jun 12, 2025 BUY Strong Buy
+13.3% avg upside
20 analysts
$130.00
26.81% Upside
 -15.0% ·
TDOC
Teladoc
 Apr 21, 2025 HOLD Buy
+241.7% avg upside
38 analysts
$8.00
6.09% Downside
 -7.8% ·
PCRX
Pacira Pharmaceuticals
 Apr 08, 2025 BUY Buy
+11.8% avg upside
23 analysts
$44.00
20.98% Upside
 -11.5% ·
PHAT
Phathom Pharmaceuticals
 Mar 19, 2025 BUY Strong Buy
+316.6% avg upside
15 analysts
$13.00
126.46% Upside
 +83.4% ·
COLL
Collegium Pharmaceutical
 Mar 17, 2025 BUY Strong Buy
+77.4% avg upside
10 analysts
$40.00
68.14% Upside
 +20.4% ·
TARS
Tarsus Pharmaceuticals
 Mar 06, 2025 BUY Strong Buy
+9.9% avg upside
17 analysts
$58.00
22.59% Downside
 +68.1% ·
VRCA
Verrica Pharmaceuticals
 Jan 06, 2025 BUY Strong Buy
+411.2% avg upside
9 analysts
$30.00
795.57% Upside
 +19.4% ·
XERS
Xeris Pharmaceuticals
 Oct 20, 2022 BUY Strong Buy
+3.9% avg upside
10 analysts
$4.00
62.75% Downside
 +235.1% ·
SLGL
Sol-Gel Technologies
 Oct 20, 2022 HOLD Strong Buy
+15.0% avg upside
6 analysts
$5.50
91.88% Downside
 -68.1% ·
HCAT
Health Catalyst
 May 10, 2022 BUY Hold
+223.1% avg upside
15 analysts
$28.00
1556.79% Upside
 -23.9% ·
BBLNF
Babylon Holdings
 Mar 04, 2022 HOLD Buy
+65549900.0% avg upside
6 analysts
$137.50
137499900.07% Upside
 · ·
AMWL
American Well
 Dec 01, 2021 HOLD Hold
+26.3% avg upside
15 analysts
$6.00
52.87% Downside
 -39.4% ·
CVS
CVS Health
 Mar 17, 2021 HOLD Strong Buy
+19.5% avg upside
39 analysts
 — +50.2% ·
SDCCQ
SmileDirectClub
 Aug 18, 2020 BUY Hold
+513999900.0% avg upside
10 analysts
$10.00
999999900.04% Upside
 · ·
AVTR
Avantor
 Oct 02, 2019 BUY Buy
+4.5% avg upside
27 analysts
$21.00
30.78% Upside
 +68.0% ·
LH
Labcorp Holdings
 Mar 16, 2016 BUY Strong Buy
-21.6% avg upside
38 analysts
 — +26.4% ·
DGX
Quest Diagnostics
 Mar 16, 2016 HOLD Buy
-26.4% avg upside
34 analysts
$72.00
71.43% Downside
 +44.6% ·
ACH
Accendra Health
 Mar 02, 2016 HOLD Sell
+6789.2% avg upside
17 analysts
 — -4.6% ·
MDRX
Veradigm
 Nov 07, 2014 BUY Buy
+196.2% avg upside
22 analysts
$15.00
199.92% Upside
 +29.2% ·
🔒 43 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Glen Santangelo — Frequently Asked Questions
How accurate are Glen Santangelo's stock ratings?
Based on the calls 13Foresight could measure, about 60% of Glen's ratings were profitable over a one-year hold, with an average return of +6.5% per rating, or +29.3% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Glen ranked on 13Foresight?
Glen Santangelo is currently ranked #1449 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Glen cover?
Glen most recently has ratings on LGND, TSE:BHC, HIMS, ALGN, INDV, CAH, IL:TEVA, VTRS, CTEV, PHR, MDLN, AMRX and 36 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.